Cocrystal Pharma Inc Stock Price, News & Analysis

Cocrystal Pharma (Nasdaq: COCP) has announced a registered direct offering priced at-the-market, consisting of 2,764,710 shares of common stock at $1.70 per share. The offering includes a concurrent private placement of unregistered warrants to purchase up to 5,529,420 shares at $1.50 per share, exercisable for 24 months.

The company expects to receive initial gross proceeds of $4.7 million, with potential additional proceeds of $8.3 million if all warrants are exercised. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is anticipated to close around September 15, 2025, with proceeds intended for working capital and general corporate purposes.

Cocrystal Pharma (Nasdaq: COCP) presented Phase 1 data for CDI-988, their lead pan-viral protease inhibitor and potential first oral antiviral for norovirus infection, at the 9th International Calicivirus Conference. The presentation highlighted CDI-988's favorable safety profile in human intestinal tissue and broad-spectrum antiviral activity against multiple norovirus genogroups.

The company recently received FDA clearance for its Investigation New Drug (IND) application to proceed with a Phase 1b human challenge study, expected to begin before year-end. The drug, developed using Cocrystal's proprietary structure-based platform technology, targets a highly conserved region in the active site of noroviruses and showed no serious adverse events in Phase 1 trials.

Cocrystal Pharma (Nasdaq: COCP) has received FDA clearance to proceed with a Phase 1b challenge study for CDI-988, their novel oral broad-spectrum protease inhibitor targeting norovirus infections. The study is expected to begin by year-end 2025.

CDI-988 represents a potential breakthrough as the first antiviral drug candidate for norovirus prevention and treatment, with no currently approved vaccines or therapeutics available. The drug has demonstrated broad-spectrum antiviral activity against major norovirus proteases including GII.4 and GII.17, and showed favorable safety in Phase 1 studies.

Cocrystal Pharma (Nasdaq: COCP) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CFO and co-CEO James Martin will deliver a company overview presentation on September 9, 2025 at 12:00 p.m. Eastern time.

The event will be held at the Lotte New York Palace Hotel, offering both in-person and virtual attendance options. Martin will be available for one-on-one meetings with institutional investors and industry professionals throughout the conference. The presentation materials are accessible on the company's website.

Cocrystal Pharma (Nasdaq: COCP) reported Q2 2025 financial results and provided updates on its antiviral drug development programs. The company's lead candidate CDI-988 showed favorable Phase 1 safety and tolerability results for norovirus treatment. A Phase 1b norovirus challenge study is planned for later in 2025.

Financial highlights include Q2 2025 net loss of $2.1 million ($0.20 per share), reduced from $5.3 million in Q2 2024. R&D expenses decreased to $1.1 million from $4.3 million year-over-year. The company reported $4.8 million in cash as of June 30, 2025.

CDI-988 demonstrated broad-spectrum activity against norovirus strains, including the prevalent GII.17 strains responsible for 2024-2025 outbreaks. The company's pipeline also includes CC-42344 for influenza treatment, which showed activity against highly pathogenic H5N1 avian influenza strains.

Cocrystal Pharma (Nasdaq: COCP) presented favorable Phase 1 results for its oral pan-viral inhibitor CDI-988 at the 2025 Military Health System Research Symposium. The study demonstrated that all doses (100 mg to 1200 mg) were well-tolerated, with lower treatment-emergent adverse events in CDI-988 subjects compared to placebo groups.

Key findings include: 28% adverse events in SAD cohorts (vs. 40% placebo) and 53% in MAD cohorts (vs. 92% placebo). No severe adverse events or significant ECG changes were reported. The company plans to initiate a Phase 1b challenge study with CDI-988 in norovirus-infected subjects later this year, addressing an unmet medical need as there are currently no approved treatments or vaccines for norovirus.

Cocrystal Pharma (Nasdaq: COCP) announced that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for oral presentation at the 9th International Calicivirus Conference in September 2025. The presentation will showcase Phase 1 study results of CDI-988, designed as a treatment for norovirus infections.

CDI-988 was developed using Cocrystal's proprietary structure-based platform technology as a broad-spectrum inhibitor targeting 3CL viral proteases. The company has completed a Phase 1 randomized, double-blind, placebo-controlled study evaluating safety, tolerability, and pharmacokinetics in healthy adults. The drug aims to address norovirus infections, which cause severe gastrointestinal illness with an estimated global societal cost of $60 billion annually.

Cocrystal Pharma (NASDAQ: COCP) announced that its broad-spectrum protease inhibitor CDI-988 will be presented at the 2025 Military Health System Research Symposium. The company's President and co-CEO, Sam Lee, will present Phase 1 results of CDI-988, which is being developed as a norovirus prophylaxis and treatment. CDI-988 is designed as a broad-spectrum inhibitor targeting 3CL viral proteases, showing potential for both norovirus and coronavirus treatment. The drug represents a potential breakthrough as there are currently no approved antiviral agents or vaccines for norovirus, which poses significant challenges in military settings. The company has completed a Phase 1 study evaluating safety, tolerability, and pharmacokinetics in healthy adults. The development utilizes Cocrystal's proprietary structure-based platform technology, which enables rapid development of antiviral therapies through detailed structural analysis and automated processes.

Cocrystal Pharma (NASDAQ: COCP) reports that its investigational drug CC-42344 shows exceptional potency against the 2024 H5N1 avian influenza strain. The drug demonstrated 1,000-fold higher potency compared to Tamiflu, with an EC50 of 0.003 µM versus 2.69 µM for Tamiflu. CC-42344 works by binding to the PB2 protein's conserved active site to inhibit viral replication. This development is particularly significant as the H5N1 virus has recently spread among U.S. dairy cattle, with some human cases reported, raising concerns about potential human-to-human transmission. The CDC's studies indicate extremely low to no population immunity to H5N1 viruses in the U.S., even among those vaccinated for seasonal flu. The company aims to address the multibillion-dollar influenza market, noting that approximately 8% of the U.S. population contracts influenza seasonally, resulting in $11.2 billion in annual direct and indirect costs.